Signal / reference entry

Tesamorelin

Also listed as Egrifta WR

Start with the scope. Follow the sources. Use the reading note to examine how a claim is supported.

Reference fields

View sources

Approval labels are specific to a product, route, and use. Read the scope and limitations together.

Status for this entry
Approved product
Evidence label
Randomized evidence

Status as of

Product and use
Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
Route context
Specified subcutaneous formulation.
Mechanism
Stimulates growth-hormone release.
Evidence
A randomized trial measured visceral fat.
Limitations
Not for weight management.
Safety
Active malignancy is a contraindication.

Sources for these reference fields

Read beyond the claim

A closer reading

A report is easier to check when you know which version you are reading. Note its publication details and look for an attached correction, update, or replacement notice. If a change is documented, examine what changed before deciding whether it affects the claim you followed. A revised table, altered explanation, and corrected typographical error would call for different kinds of checking. Keep the earlier claim beside the current wording so the difference remains visible. The goal is a traceable reading record, with any unresolved version question stated clearly.

Questions to take to the source

  1. Which version of the report does the linked claim appear to use?
  2. Does any correction change the passage or table supporting this claim?
  3. Can I explain the effect of the revision without guessing its importance?

Filed under

  • Hormones

Topics organize the index; they do not describe a recommended use.

Sources

These references support the reference fields as a group. Follow each link to inspect its scope and wording.

  1. EGRIFTA WR NLM · Checked
  2. Falutz trial PubMed · Checked

Educational reference material. No clinician review is claimed. This entry does not provide personal medical advice.